DGI
MYGN icon

Disciplined Growth Investors’s Myriad Genetics MYGN Stock Holding History

Disciplined Growth Investors’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-753,956
Closed -$4M – 67
2025
Q2 		$4M Sell
753,956
-3,979,736
-84% -$23.5M 0.08% 55
2025
Q1 		$42M Buy
4,733,692
+2,177,113
+85% +$26.1M 0.87% 34
2024
Q4 		$35.1M Buy
2,556,579
+29,144
+1% +$538K 0.67% 39
2024
Q3 		$69.2M Buy
2,527,435
+440,107
+21% +$11.9M 1.31% 26
2024
Q2 		$51.1M Buy
2,087,328
+10,035
+0.5% +$220K 0.96% 29
2024
Q1 		$44.3M Buy
2,077,293
+122,057
+6% +$2.62M 0.81% 32
2023
Q4 		$37.4M Sell
1,955,236
-18,076
-0.9% -$313K 0.82% 31
2023
Q3 		$31.7M Sell
1,973,312
-36,490
-2% -$694K 0.75% 35
2023
Q2 		$46.6M Sell
2,009,802
-78,982
-4% -$1.72M 1.05% 30
2023
Q1 		$48.5M Sell
2,088,784
-183,660
-8% -$3.73M 1.25% 30
2022
Q4 		$33M Sell
2,272,444
-6,046
-0.3% -$113K 0.84% 33
2022
Q3 		$43.5M Buy
2,278,490
+377,703
+20% +$8.67M 1.21% 27
2022
Q2 		$34.5M Buy
1,900,787
+26,309
+1% +$546K 0.93% 33
2022
Q1 		$47.2M Buy
1,874,478
+27,988
+2% +$716K 1.03% 35
2021
Q4 		$51M Sell
1,846,490
-38,542
-2% -$1.12M 1.03% 38
2021
Q3 		$60.9M Buy
1,885,032
+6,211
+0.3% +$206K 1.21% 35
2021
Q2 		$57.5M Buy
1,878,821
+50,690
+3% +$1.46M 1.1% 36
2021
Q1 		$55.7M Sell
1,828,131
-249,944
-12% -$7.09M 1.13% 34
2020
Q4 		$41.1M Sell
2,078,075
-55,802
-3% -$901K 0.79% 42
2020
Q3 		$27.8M Sell
2,133,877
-60,327
-3% -$763K 0.65% 44
2020
Q2 		$24.9M Sell
2,194,204
-835,141
-28% -$11.9M 0.6% 46
2020
Q1 		$43.4M Buy
3,029,345
+171,330
+6% +$3.62M 0.99% 37
2019
Q4 		$77.8M Buy
2,858,015
+75,988
+3% +$2.09M 1.28% 33
2019
Q3 		$79.6M Buy
2,782,027
+74,663
+3% +$2.18M 1.47% 28
2019
Q2 		$75.2M Sell
2,707,364
-144,700
-5% -$4.09M 1.4% 28
2019
Q1 		$94.7M Buy
2,852,064
+1,511,931
+113% +$46M 1.66% 22
2018
Q4 		$39M Sell
1,340,133
-17,218
-1% -$619K 0.8% 44
2018
Q3 		$62.4M Buy
1,357,351
+55,826
+4% +$2.48M 1.05% 35
2018
Q2 		$48.6M Sell
1,301,525
-19,646
-1% -$664K 0.9% 41
2018
Q1 		$39M Sell
1,321,171
-26,657
-2% -$902K 0.77% 46
2017
Q4 		$46.3M Sell
1,347,828
-279
-0% -$9.41K 0.91% 39
2017
Q3 		$48.8M Sell
1,348,107
-13,425
-1% -$383K 1.02% 37
2017
Q2 		$35.2M Buy
1,361,532
+2,335
+0.2% +$49.6K 0.73% 46
2017
Q1 		$26.1M Sell
1,359,197
-9,438
-0.7% -$167K 0.58% 49
2016
Q4 		$22.8M Buy
1,368,635
+16,278
+1% +$295K 0.52% 51
2016
Q3 		$27.8M Sell
1,352,357
-4,825
-0.4% -$122K 0.66% 48
2016
Q2 		$41.5M Buy
1,357,182
+37,700
+3% +$1.31M 1.04% 37
2016
Q1 		$49.4M Sell
1,319,482
-29,325
-2% -$1.1M 1.26% 31
2015
Q4 		$58.2M Sell
1,348,807
-30,125
-2% -$1.27M 1.47% 26
2015
Q3 		$51.7M Buy
1,378,932
+15,700
+1% +$557K 1.32% 30
2015
Q2 		$46.3M Buy
1,363,232
+8,525
+0.6% +$290K 1.12% 33
2015
Q1 		$48M Buy
1,354,707
+493,300
+57% +$17.7M 1.13% 31
2014
Q4 		$29.3M Sell
861,407
-5,925
-0.7% -$210K 0.7% 48
2014
Q3 		$33.5M Buy
867,332
+27,000
+3% +$1.01M 0.86% 41
2014
Q2 		$32.7M Sell
840,332
-26,180
-3% -$974K 0.85% 42
2014
Q1 		$29.6M Buy
866,512
+38,475
+5% +$1.19M 0.75% 46
2013
Q4 		$17.4M Buy
828,037
+33,157
+4% +$839K 0.45% 57
2013
Q3 		$18.7M Buy
794,880
+20,360
+3% +$578K 0.54% 52
2013
Q2 		$20.8M Buy
+774,520
New +$22.4M 0.67% 44

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Disciplined Growth Investors's MYGN Position: Q3 2025 in Review

Disciplined Growth Investors sold out of Myriad Genetics (MYGN) in Q3 2025, closing a stake of 753,956 shares — an estimated $4M sold.

Disciplined Growth Investors first reported a position in MYGN in Q2 2013 and held it in 49 quarters. The position peaked at $94.7M in Q1 2019. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2025.

  • Disciplined Growth Investors reported no remaining Myriad Genetics position as of Q3 2025 after selling out during the quarter.
  • Disciplined Growth Investors sold 753,956 Myriad Genetics shares in Q3 2025, an estimated $4M.
  • Disciplined Growth Investors first reported a position in Myriad Genetics in Q2 2013 and held it in 49 quarters.
  • Disciplined Growth Investors's Myriad Genetics position peaked at $94.7M in Q1 2019.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2025.

Based on Disciplined Growth Investors's 13F filing for Q3 2025, filed 14 Nov 2025.